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The Impact of Folic Acid and Vitamin B12 Supplementa-
tion on Blood Pressure and Arterial Stiffness in Subjects
with Subnormal Micronutrient Intake
K.S. Woo1,∗, P. Chook1, L.L.T. Chan1, D.S. Celermajer 2
1 The Chinese University of Hong Kong, Hong Kong; 2 The
University of Sydney, Sydney, Australia
Introduction: Folic acid (FA) supplementation improves
atherogenic processes in coronary and asymptomatic sub-
jects, but its impact onbloodpressure andarterial stiffness
remains unknown.
Methods: 207 asymptomatic subjects (aged 45± 8 years)
in rural northern China were randomised to take FA
(5mg/day), vitamin B12 (500g/day), B12 + FA or placebo
in double-blinded design for 6 months, followed by
open-label B12 + FA for 6moremonths. Radial artery aug-
mentation index (AI) and pulse wave velocity (PWV) were
measured by SphygmoCor.
Results: Blood B12 and folate levels were low at base-
line, but significantly increased after FA, B12 andB12+FA,
and not after placebo treatment, while fasting homo-
cysteine decreased significantly after FA and B12+FA
treatments (p< 0.001). Systolic (SBP) or diastolic pressures
(DBP) decreased marginally (p< 0.05) during placebo and
all three active treatment periods (p< 0.001). There was no
significant change in AI or PWV.
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(CHD) in New Zealand in 2001–2003 using routinely col-
lected data.
Method: We estimated incidence from the sum of first
CHDhospital admissionsandout-of-hospitalCHDdeaths
without a hospital admission in the preceding 5 years.
Mortality was calculated from the sum of deaths coded
to CHD and to related causes but with prior hospitali-
sation for CHD. We collated data from the New Zealand
Health Information Service and carried out record linkage
using the unique national identifier used throughout the
New Zealand health care system. From these estimates,
we built multi-state lifetables and thereby calculated esti-
mates for prevalence, survival, lifetable risk, and median
age at onset.
Results: The lifetime risk of acquiring CHDwas estimated
at 35% for males and 28% for females, prevalence rising
from around 2% for males and 0.5% for females at age
40–44 and to around 18% and 12%, respectively at age
85–89.Medianageat onset ofCHDwas67.5 years formales
and 77.5 years for females. Median survival duration from
the initial event was 9.5 years for males and 6.2 years for
females. On average, males with CHD lost 6.9 years of life
expectancy and females 5.7 years.
Conclusion: We have developed an internally consistent
picture of the descriptive epidemiology of CHD for the
whole New Zealand population in 2001–2003 which hasPlacebo (n= 53) B12 (n= 52)
0 month 6 months 0 month 6 m
FA (nmol/l) 10.4 ± 2.9 12.3 ± 7.5 10.4 ± 2.9 12
B12 (pg/l) 201 ± 113 173 ± 81 214 ± 109 30
SBP (mmHg) 128 ± 14 124 ± 17* 131 ± 20 13
DBP (mmHg) 85 ± 8.5 82 ± 10* 87 ± 12 8
Compared with baseline: *p< 0.05; **p< 0.001; ***p< 0.0001.
Sustained decrease in SBP (p= 0.001) and DBP (p< 0.0001)
were observed after open-label FA+B12 treatment, asso-
ciated with a significant decrease in AI (135± 22% to
122± 21%; p< 0.001).
Conclusion: Long-term FA and B12 supplementation
improves blood pressure and arterial stiffness in subjects
with subnormal intake.
doi:10.1016/j.hlc.2008.05.199
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Coronary Heart Disease in New Zealand 2001–2003: Esti-
mates of Incidence and Prevalence Based on Routinely
Collected Data
Martin Tobias 1, Wing-Cheuk Chan2, Craig Wright 1, Rod
Jackson2, Stewart Mann3,∗, Li-Chia Yeh1
1 Public Health Intelligence, Ministry of Health, Wellington,
New Zealand; 2 Department of Public Health, University of
Auckland, Auckland, New Zealand; 3 Department of Medicine,
University of Otago, Wellington, New Zealand
Objective: We wished to estimate the incidence, preva-
lence, survival and mortality of coronary heart diseaseFA (n= 51) B12 + FA (n= 51)
0 month 6 months 0 month 6 months
5 10.7 ± 5.0 28.7 ± 19.2*** 13.1 ± 8.3 25.3 ± 18.1***
1** 182 ± 88 163 ± 86 188 ± 109 289 ± 170***
126 ± 20 119 ± 19** 134 ± 20 126 ± 24**
** 83 ± 11 79 ± 10** 88 ± 9 81 ± 11***
relevance to prioritisation and planning of relevant health
care services.
doi:10.1016/j.hlc.2008.05.200
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Irukandji Syndrome, Cause for Troponin Leak and Stress
Cardiomyopathy
Keith Tiong1,2,∗, Sang-Won Jin1,2, Jamie Seymour1,2,
Peter Pereira 1,2
1 Cairns Base Hospital, Cairns, Queensland, Australia; 2 James
Cook University, Cairns, Queensland, Australia
Introduction: Carukia Barseni (also known as Irukandji)
is a type of box jelly fish unique to North Queensland.
We present a case series of irukandji syndrome which
presented to Cairns Base Hospital recently.
Method/Design: Consents were obtained by all subjects.
Regular observations were performed, baseline electro-
cardiograms, serial serumtroponins anddifferentialwhite
cell counts. Serial transthoracic echocardiograms were
performed in cases of positive troponins.
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Results: Four cases with positive troponins were identi-
fied. The age group range from 14 to 40 years of age,
median age 24.3 are males and 1 female. These cases
presents within 24 h of contact. Two cases were docu-
mented with persistent hypertension, one with persistent
tachycardia, three with heart rate variabilities. Only two
electrocardiograms were abnormal. Intravenous magne-
sium and/or nitrates infusion were given in three of the
cases. The eosinophils counts were normal in all cases.
These were associated with a rise in the level of serum
troponins. Serial transthoracic echocardiogramswereper-
formed to identify the cause of troponin rise which
included regional wall motion abnormalities, left ventric-
ular function by Simpson’s method and tissue doppler
imaging. Therewereonly one case of impaired left ventric-
ular function, identifiedas a caseof stress cardiomyopathy.
Conclusion: Irukandji syndrome is associated with sud-
den catecholamines release. The sympathetic overdrive is
a cause of transient troponin rise,which precipitates stress
cardiomyopathy.
doi:10.1016/j.hlc.2008.05.201
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Angiotensin-Converting Enzyme Inhibition Reduces Left
Ventricular Outflow Tract Diameter in Marfan Syndrome;
Potential Role of Reduced Transforming Growth Factor-
Signalling
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+3± 1 ng/ml, p= 0.02), MMP-2 levels by 22± 6 ng/ml
(placebo +8± 3 ng/ml, p< 0.001), and MMP-3 levels by
5± 1 ng/ml (placebo +2± 1 ng/ml, p< 0.001). There were
moderately strong correlations between the pre/post
intervention change in LVOT diameter and the change
in both latent (r= 0.49, p= 0.04) and active TGF- (r= 0.74,
p= 0.002), MMP-2 (r= 0.75, p= 0.001), and MMP-3 plasma
levels (r= 0.81, p< 0.0001).
Conclusion: ACE inhibition reduced LVOT diameter in
MFS patients possibly through attenuation of TGF-
signalling. Plasma TGF- could be a useful prognostic
indicator of progression of aortic dilatation and response
to therapy in MFS.
doi:10.1016/j.hlc.2008.05.202
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Outcome & Prognostic Factors on 57 Cases Of Infective
Endocarditis in a Single Center
Chi Wing Wong ∗, Jonathan Tisch, Graeme Porter, Calum
Young, Bryan Dwyer
Tauranga Hospital, Tauranga, New Zealand
A single centre retrospective review of all cases of IE for a
5-year period from June 2002. Therewere 57 episodes of IE
in 47patients. Seventypercentweredefinite IEusingmod-
ified Duke Criteria (2000). Forty-five episodes were native
v
e
T
w
T
c
p
r
E
p
c
f
i
r
A
f
l
a
p
n
f
C
1
2nna Ahimastos 1,∗, Anuradha Aggarwal 2, Kellie
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avarirayan2, Anthony Dart 1, Bronwyn Kingwell 1
Baker Heart Research Institute,Melbourne, Australia; 2 Royal
elbourne Hospital, Melbourne, Australia
ackground: We have previously shown that the
ngiotensin-converting enzyme (ACE) inhibitor perindo-
ril reduced aortic diameter by 3–7mm in Marfan
yndrome (MFS) patients (p< 0.0001). Excessive signalling
y the transforming growth factor- (TGF-), which also
ontributes to matrix metalloproteinase (MMP) activation
nd extracellular matrix degeneration, is believed to play
crucial role in the development of aortic dilatation. We
ypothesised that reduction in aortic diameter would cor-
elate with reduction in plasma TGF- and MMP levels.
ethods: 17 MFS patients (aged 33± 5 (mean±S.D.))
n standard -blocker therapy were randomised to also
eceive either perindopril (8mg od, n= 10) or placebo
n= 7) for 24 weeks in a double blind study. Venous blood
amples were analysed for latent and active TGF-, and
MP-2 and MMP-3 levels.
esults: Compared to placebo perindopril significantly
educed left ventricular outflow tract (LVOT) diameter
y 2.8± 0.4mm (placebo +1.1± 0.3mm, p< 0.0001), latent
GF- levels by 14.0± 4.5 ng/ml (placebo +2.0± 2.3 ng/ml,
= 0.01), active TGF- levels by 4± 1 ng/ml (placebo,alve endocarditis, the remaining were prosthetic valve
ndocarditis and one case of pacemaker lead endocarditis.
he mitral valve was most commonly involved. Mean age
as 66 with bimodal peak at age group 21–30 and 81–90.
he most commonly isolated organisms were Strepto-
occi (37%) and Staphylococcus Aureus (35%). Forty-nine
ercent of patients remained event-free (survive without
ecurrence or operation) at the end of follow-up period.
ight patients had recurrent endocarditis within the study
eriod. Five cases (8.5%) had early recurrence of endo-
arditis within 60 days. Twelve patients (26%) died during
ollow-up (mean 14 months). There was no significant
ncrease in mortality of patients with history of recur-
ent endocarditis (38% vs. 28%; p= 0.39). Staphylococcus
ureus was associated with increased mortality or need
or valve surgery (OR 4.5; 95% CI 1.38–14.8), risk of neuro-
ogical events (OR 8.9; 1.5–52), renal failure (OR 7.2; 1.7–30)
nd thrombocytopenia (OR 5.6; 1.4–22). Haematological
arameters, renal function or inflammatorymarkers were
ot shown to be predictive of increased mortality or need
or valve surgery.
onclusion:
. The mortality of IE remains high. Less than half of this
cohort remained event-free.
. Themicro-organisminvolved ismorepredictiveofmor-
tality or need for surgery than recurrent endocarditis.
